Abstract
Purpose
To compare the additive intraocular pressure (IOP)-lowering effects of latanoprost 0.005% and brimonidine 0.2% in primary open-angle glaucoma (POAG) patients uncontrolled on fixed combination of timolol 0.5% and dorzolamide 2% (TDC) alone.
Methods
In all, 80 eyes of 80 POAG patients with IOP inadequately controlled by TDC were randomly assigned to receive either latanoprost 0.005% or brimonidine 0.2%. IOP measurements were recorded at 1000 (peak effect) and 1600 (trough effect) on day 0 (baseline) and at 1 and 3 months. At each stage and time point, the mean IOP reductions from baseline were evaluated for both groups, and success rates (minimum 15% reduction) were determined.
Results
At baseline, the mean peak/trough IOPs with TDC were 20.2/21.6 and 19.9/21.4 mmHg in latanoprost and brimonidine groups, respectively. Latanoprost+TDC reduced the mean peak/trough IOP by 4.4/3.4 and 5.2/3.5 mmHg at 1 and 3 months. The corresponding values for brimonidine+TDC were 3.9/2.9 and 4.6/2.9 mmHg. Each of these results represented a significant reduction from baseline (P<0.001 for all); however, the groups’ peak/trough reductions from baseline did not differ at any time point (P>0.05 for all). With the latanoprost+TDC combination, the peak/trough success rates at 1 and 3 months were 76.3%/42.1% and 77.1%/40%. The corresponding values with the brimonidine+TDC combination were 71.8%/41% and 77.7%/41.7%. There were no significant differences in the groups’ success rates at any time point (P>0.05 for all).
Conclusion
Addition of latanoprost 0.005% or brimonidine 0.2% to TDC reduces peak/trough IOPs significantly and the effects of these combinations are comparable.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt J et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol 1991; 109: 1090–1095.
Kass MA, Heuer DK, Higginbotham EJ, Johnson JA, Keltner JL, Miller JP et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701–713.
The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429–440.
Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108: 1943–1953.
Leske CM, Connell AM, Wu SY, Hyman LG, Schachat AP . Risk factors for open-angle glaucoma. The Barbados Eye Study. Arch Ophthalmol 1995; 113: 918–924.
DesMarchais B, Candal E, Weitzman M, Shields MB . Effect of latanoprost as adjunctive therapy. Can J Ophthalmol 2000; 35: 214–217.
Watson P, Stjernschantz J . Latanoprost Study Group. A six-moth, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996; 103: 126–137.
Simmons ST, Samuelson TW, Alphagan/Xalatan Study Group. Comparison of brimonidine with latanoprost in the adjunct treatment of glaucoma. Clin Ther 2000; 22: 388–399.
O’Connor DJ, Martone JF, Mead A . Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol 2002; 133: 836–837.
Simmons ST, Earl ML, Alphagan/Xalatan Study Group. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering. Ophthalmology 2002; 109: 307–314.
Kampik A, Arias-Puente A, O’Brart DP, Vuori ML, The European Latanoprost Study Group. Intraocular pressure- lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study. J Glaucoma 2002; 11: 90–96.
Higginbotham EJ, Feldman R, Stiles M, Dubiner H, Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol 2002; 120: 915–922.
Arici MK, Sayici M, Toker M, Erdogan H, Topalkara A . A short term study of the additive effect of timolol and brimonidine on intraocular pressure. Eye 2002; 16: 39–43.
Clineschmidt CM, Williams RD, Snyder E, Adamsons IA, The Dorzolamide-Timolol Combination Study Group. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide–timolol combination to monotherapy with timolol or dorzolamide. Ophthalmology 1998; 105: 1952–1959.
Strahlman ER, Vogel R, Tipping R, Clineschmidt CM, The Dorzolamide Additivity Study Group. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology 1996; 103: 1283–1293.
Choudhri S, Wand M, Shields MB . A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am J Ophthalmol 2000; 130: 832–833.
Suzanna Jr R, Nicolela MT, Oga E . Additive effect of latanoprost to the combination of timolol and dorzolamide. J Glaucoma 2000; 9: 183–186.
Hughes E, Spry P, Diamond J . 24-hour monitoring of intraocular pressure in glaucoma management: a retrospective review. J Glaucoma 2003; 12: 232–236.
Sacca SC, Rolando M, Marletta A, Macri A, Cerqueti P, Ciurlo G . Fluctuations of intraocular pressure during the day in open-angle glaucoma, normal-tension glaucoma and normal subjects. Ophthalmologica 1998; 212: 115–119.
Wilensky JT, Gieser DK, Dietsche ML, Mori MT, Zeimer R . Individual variability in the diurnal intraocular pressure curve. Ophthalmology 1993; 100: 940–944.
David R, Zangwill L, Briscoe D, Dagan M, Yagev R, Yassur Y . Diurnal intraocular pressure variations: an analysis of 690 diurnal curves. Br J Ophthalmol 1992; 76: 280–283.
Author information
Authors and Affiliations
Corresponding author
Additional information
This study is presented at the annual meeting of the American Academy of Ophthalmology, Orlando, FL, October 2002.
Rights and permissions
About this article
Cite this article
Akman, A., Cetinkaya, A., Akova, Y. et al. Comparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol–dorzolamide combination. Eye 19, 145–151 (2005). https://doi.org/10.1038/sj.eye.6701428
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6701428
Keywords
This article is cited by
-
Brimonidine prevents neurodegeneration in a mouse model of normal tension glaucoma
Cell Death & Disease (2014)
